Publication trends of dexmedetomidine and perioperative cognitive dysfunction: A bibliometric analysis from 1995 to 2024

右美托咪定与围手术期认知功能障碍的发表趋势:1995年至2024年的文献计量分析

阅读:1

Abstract

INTRODUCTION: Dexmedetomidine (Dex) has shown potential in mitigating perioperative cognitive dysfunction (POCD). This study aimed to systematically evaluate the research hotspots and development trends in Dex and POCD using bibliometric analysis. METHODS: A systematic search was conducted on the Web of Science Core Collection database to identify publications related to Dex and POCD from 1995 to 2024. Bibliometric analysis was performed using VOSviewer (V 1.6.20), CiteSpace (V 6.3.R1), and R V4.3.3. RESULTS: A total of 585 articles on Dex and POCD between 1995 and 2024 were analyzed. These articles involved 1688 authors from 1857 institutions across 140 countries or regions, published in 240 journals, and citing 12,881 sources. The annual growth rate of publications in this field was 16.21%, with a peak of 91 articles in 2021. China led in the number of articles (n = 379), multiple country publications (MCP = 29), and total citations = 4989). The USA ranked second with 74 articles, 18 MCPs, and 2608 citations, followed by South Korea with 29 articles and 533 citations. Harvard University published the most articles (n = 51). Wang Dong-Xin was the most influential author, with an h-index of 7. Anesthesiology led the high-impact journals with an H-index of 11. The keyword analysis identified "neuroinflammation," "risk," "injury," and "efficacy" as the latest research themes. CONCLUSION: This bibliometric analysis provides a comprehensive overview of the research trends regarding Dex and POCD. Future research should continue to explore the mechanisms, efficacy, and safety of Dex in preventing POCD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。